Michel Le May, MD; George Wells, PhD; Derek So, MD; et al.
free access
JAMA Cardiol. 2020;5(2):126-134. doi:10.1001/jamacardio.2019.4852
This multicenter randomized clinical trial conducted in Canada assesses whether 30-day all-cause mortality differs with the use of radial access or femoral access for primary percutaneous coronary intervention among referred patients with ST-segment elevation myocardial infarction.
Ambarish Pandey, MD, MSCS; Neil Keshvani, MD; Rohan Khera, MD; et al.
free access
JAMA Cardiol. 2020;5(2):136-145. doi:10.1001/jamacardio.2019.4845
This cohort study assesses temporal trends in 30-day readmission and mortality rates among black and nonblack patients discharged after hospitalization for acute myocardial infarction at hospitals defined as low-performing and high-performing per their Hospital Readmissions Reduction Program penalty status.
Kasra Moazzami, MD, MPH; Bruno B. Lima, MD, PhD; Mohammad Hammadah, MD; et al.
free access
JAMA Cardiol. 2020;5(2):147-155. doi:10.1001/jamacardio.2019.4528
This cohort study of 454 patients with stable coronary artery disease investigates the association between the change in circulating progenitor cell counts during exercise and the risk of adverse cardiovascular events among patients with and without stress-induced myocardial ischemia.
Sameer Hirji, MD, MPH; Siobhan McGurk, BS; Spencer Kiehm, BA; et al.
free access
has audio
JAMA Cardiol. 2020;5(2):156-165. doi:10.1001/jamacardio.2019.4657
This cohort study of Medicare beneficiaries compares 30-day vs 90-day mortality as a hospital performance metric for transcatheter aortic valve replacement and surgical aortic valve replacement.
-
Audio Author Interview:
Utility of 90-Day vs 30-Day Mortality Quality Metrics for Aortic Valve Replacement Outcomes
-
Invited Commentary
Ninety-Day Outcome Assessment After Transcatheter and Surgical Aortic Valve Replacement—Is the Juice Worth the Squeeze?
Michael Mack, MD; Karim Al-Azizi, MD; Michael J. Reardon, MD
JAMA Cardiol
-
Audio Author Interview:
Utility of 90-Day vs 30-Day Mortality Quality Metrics for Aortic Valve Replacement Outcomes
Kelly H. Schlendorf, MD; Sandip Zalawadiya, MD; Ashish S. Shah, MD; et al.
free access
JAMA Cardiol. 2020;5(2):167-174. doi:10.1001/jamacardio.2019.4748
This case series examines the association between use of hearts from hepatitis C–positive donors for US patients undergoing heart transplant and heart transplant volumes, wait-list duration, the transmission and cure of donor-derived hepatitis C, and morbidity and mortality at 1 year.
Megan McCullough, MD; Cesar Caraballo, MD; Neal G. Ravindra, MPhil; et al.
free access
JAMA Cardiol. 2020;5(2):175-182. doi:10.1001/jamacardio.2019.4965
This registry-based cohort study analyzes the association between varying combinations of neurohormonal blockade therapies and survival and quality of life in adult patients with left ventricular assist devices.
Ravi B. Patel, MD; Laura A. Colangelo, MS; Jared P. Reis, PhD; et al.
free access
JAMA Cardiol. 2020;5(2):184-192. doi:10.1001/jamacardio.2019.4867
This cohort study describes the trajectory of albuminuria as measured by urine albumin-to-creatinine ratio across a 20-year span and evaluates the association of albuminuria trajectory with echocardiographic indices of structure and function in middle age.
Angela Lowenstern, MD; Karen P. Alexander, MD; C. Larry Hill, PhD; et al.
free access
JAMA Cardiol. 2020;5(2):193-201. doi:10.1001/jamacardio.2019.4973
This prespecified analysis of the PROMISE randomized clinical trial determines whether the prognostic utility of anatomic vs functional testing for coronary artery disease varies based on patient age.